The 2022 International Multi-center Clinical Trial Summit Forum (Jinling Multinational Corporations) is about to begin!

Multi-regional Clinical Trials (MRCT) has gradually become an efficient mode for the global simultaneous research and development of new drugs and new medical devices, and more and more multinational companies choose China as an important base
for international multi-center clinical trials 。 However, MRCT is more complex than general clinical trials in terms of design, implementation, analysis and management, and factors such as the selection of PI, the selection of test centers, the scientificity of trial objectives and endpoint indicators, and whether the clinical trial protocol design is scientific, standardized, ethical, and operable will play an important role
in the success of the trial.
At this stage, the number of innovative enterprises participating in MRCT in China is still relatively limited, but with the rapid development of innovative drug research in China, it is expected that China's innovative drugs will enter the growth period
of MRCT projects in the next few years.

The rich mature experience of MRCT owned by multinational companies has important reference significance for China's innovative pharmaceutical and device enterprises, testing institutions, CROs, SMO and other clinical trial participants
.
With the implementation of a series of important measures for open innovation of the whole industry chain of Nanjing biomedicine, the Nanjing Biomedical Industry Innovation and Transformation Center, promoted by the Nanjing New Medicine and Life and Health Industry Chain Work Class, will be committed to promoting multi-party collaboration in the clinical trial ecosystem, improving the speed of international and domestic multi-center clinical trials, accelerating the research and development of international innovative drugs and devices, and promoting the transformation of
global innovative drug and device achievements.

The "2022 International Multi-center Clinical Trial Summit Forum (Jinling Multinational Corporations)" hosted by China Biomedical Industry Chain Innovation and Transformation Alliance and Nanjing Biomedical Industry Innovation and Transformation Center, covered international multi-center clinical trials/research hotspots such as innovative drugs, medical devices, vaccines, early clinical research, real-world research, decentralized clinical trials (DCT) and other international multi-center clinical trials/research hotspots, and the scope of discussion covered MRCT hot countries and regions such as the United States, Australia, Japan, and Hong Kong.
More than 10 leading multinational companies will share the valuable experience and practical practices of international multi-center clinical trials
.
It is believed that it will broaden the horizons of the participants, supplement their perspectives, convey cutting-edge information in the industry, and jointly promote the standardization and rapid development
of MRCT in China.